Page 171 - 16Neonatal Jaundice_compressed
P. 171
Neonatal jaundice
the best interests of the child paramount. Local procedures should be in place to support
communication with parents in this situation.
The evidence for effectiveness of clofibrate in neonatal jaundice is strong but is confined to one
population. The GDG notes that studies of clofibrate in adults reported significant adverse effects.
227
While these findings cannot be directly extrapolated to neonates, this concern, together with the
paucity of data, led the GDG to conclude that clofibrate cannot currently be recommended for use
in neonatal jaundice. However, the GDG considered that further investigations in UK populations
was required and made a research recommendation on this topic.
No other interventions are recommended for the treatment of hyperbilirubinemia.
Recommendations – 7.4 Other treatments
Use intravenous immunoglobulin (IVIG) (500 mg/kg over 4 hours) as an adjunct to
continuous multiple phototherapy in cases of Rhesus haemolytic disease or ABO haemolytic
disease when the serum bilirubin continues to rise by more than 8.5 micromol/litre per hour.
Do not use any of the following to treat hyperbilirubinaemia:
• agar
• albumin
• barbiturates
• charcoal
• cholestyramine
• clofibrate
• D-penicillamine
• glycerin
• manna
• metalloporphyrins
• riboflavin
• traditional Chinese medicine
• acupuncture
• homeopathy.
7.5 Satisfaction with treatment
Description of included studies
No studies were identified.
Review findings
No studies were identified.
Evidence summary
No evidence has been identified.
140